Trials / Completed
CompletedNCT01543191
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
A Phase 1 Dose-escalation Study TO Evaluate the Safety and Tolerability of PUR118 and Placebo in Subjects With CF
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Pulmatrix Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether PUR118 is safe and tolerable in a population of subjects with Cystic Fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PUR118 | low dose and high dose for 3 doses, BID |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2012-03-02
- Last updated
- 2013-07-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01543191. Inclusion in this directory is not an endorsement.